Coridon ついに発つ！

最近、銭形も非常～に注目している Coridon さんに関する情報です！

「スゴイぞCoridon！HSV完治ワクチン？」でも紹介しているように、Ian Frazer 教授のHSV2に対する動物実験結果は実にスゴイもので、Coridon教授の実験では100％、ワシントン大学の実験では90～100％ウイルスの感染を阻止することができたようです！以前の記事については先のリンクで確認して欲しいのですが、今回は以下の記事から読み取れる新しい情報をまとめてみたいと思います。





まず、2000年に設立された Coridon Pty Ltd という企業ですが、どうやらクィーンズランド大学がベンチャー企業として始めたもののようで、現在、臨床治験（Phase I）に入る準備を進めているところのようです。

Ian Frazer先生は、クィーンズランド大学にあるDiamantina Instituteという研究施設で、自ら開発した技術を応用したワクチン研究を進めてこられたようですが、先の動物実験で非常に優秀な成績を残したおかげで、最大支援者である Allied Health Care Group から追加の資金援助を受けられることとなり、ワクチンの製造と治験の準備を精力的に進めているようdす！

今回の記事でも、「Coridon最適化法」に関する具体的な情報は得られなかったのですが、この最適化法は各国の研究者による共同研究のお蔭であり、ウイルス治療研究に非常に大きな影響を与えるもののようです…。

今回の記事で、私銭形が「ホッ」としたのは、

“We are very excited at The University of Queensland Diamantina Institute to be partnering with Coridon in developing this breakthrough vaccine technology, which promises to both prevent and treat infections with HSV-2, which causes a common and unpleasant viral illness,” Professor Brown said.

という部分でして、「この新薬が感染者を対象とした治療薬としても効果を表す可能性がある」というところです…。


銭形個人の感想で言えば、

　　これまでは、AIC316がメインだったのに、いきなり主役がドドーンと出てきた！

といった感じを受けています…。


まぁ、利用者の立場からすれば、

　　「どっちでもいいから、兎に角頑張ってくれい！」

ということでしょうか…（汗）



UQ start-up research offers hope for herpes sufferers

http://www.uq.edu.au/news/?article=23959

A University of Queensland (UQ) start-up company, Coridon Pty Ltd, established to commercialise Professor Ian Frazer's work in developing next generation DNA vaccines, has successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 (HSV-2) vaccine, with outstanding results.

The company will now look to progress the program into clinical studies.

Working at the UQ Diamantina Institute, Coridon is developing DNA vaccines for the prevention and treatment for a range of infectious diseases and cancers in humans, utilising the company's patented technology.

Collaborating with Professor David Koelle and his colleagues at the University of Washington in Seattle, Coridon tested a number of different formulations of Coridon's prototype vaccine. These proved 100% effective at protecting animals against HSV-2 infection, confirming an earlier study with the University of Washington which also demonstrated 90-100% protection against infection.

These results were presented at the 5th Vaccine and ISV Annual Global Congress in Seattle earlier this month.

Professor Ian Frazer said Coridon has now secured additional funding from major investor Allied Healthcare Group (ASX: AHZ) to begin manufacturing the vaccine and conduct pre-clinical safety studies before testing the vaccine in a Phase I clinical study.

“The results of our herpes vaccine mark the beginning of an exciting period," Professor Frazer said.

"Over the next 12 months, we expect pivotal data showing that our HSV vaccine, which incorporates Coridon optimisation technology, produces similar immune responses in the clinic to those seen in the animal trials.”

Professor Matt Brown, Director of The University of Queensland Diamantina Institute, said the collaborative approach with researchers and Coridon has paved the way for the success of such critical technology.

“We are very excited at The University of Queensland Diamantina Institute to be partnering with Coridon in developing this breakthrough vaccine technology, which promises to both prevent and treat infections with HSV-2, which causes a common and unpleasant viral illness,” Professor Brown said.

“This vaccine success is made possible by bringing together UQDI's excellence in immunology research with private industry and other leading international researchers.”

“We look forward to working with Coridon in developing this vaccine as it moves towards clinical trials.”

Allied Healthcare Group's Managing Director, Mr Lee Rodne said the data provides fantastic validation to the Coridon platform which could be applied to a number of infectious diseases.

"We are excited about the path forward for the program as it moves toward clinical studies,” Mr Rodne said.

Professor Frazer's work at Coridon follows the success of his discovery with the late Dr Jian Zhou of a basis for cervical cancer vaccine Gardasil, also commercialised by UniQuest.